Expanded Access to Investigational, Unapproved Medicines

We believe that our fastest path to fulfill our commitment to patients is to focus on working with the FDA to complete the required clinical studies needed to demonstrate safety and effectiveness of our investigational therapy Toca 511 & Toca FC for multiple cancer indications. This focus on completing our clinical trials will help us expeditiously achieve the best outcome for the greatest number of adults and children suffering from cancer.

Currently, Tocagen does not have an Expanded Access Program (EAP) for any advanced cancers. We plan to have an EAP once the data from our ongoing Toca 5 study is available for adults with recurrent High Grade Gliomas. In the interim, details of our ongoing clinical trials are available on the clinical trials section of our website. We encourage patients to discuss their treatment options, including clinical trials, with their medical team, and contact any of the several patient advocacy organizations listed below for resources, research and support.